Literature DB >> 24843155

Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.

Olivia Twu1, Daniele Dessí2, Anh Vu3, Frances Mercer3, Grant C Stevens3, Natalia de Miguel4, Paola Rappelli2, Anna Rita Cocco2, Robert T Clubb5, Pier Luigi Fiori2, Patricia J Johnson6.   

Abstract

The human-infective parasite Trichomonas vaginalis causes the most prevalent nonviral sexually transmitted infection worldwide. Infections in men may result in colonization of the prostate and are correlated with increased risk of aggressive prostate cancer. We have found that T. vaginalis secretes a protein, T. vaginalis macrophage migration inhibitory factor (TvMIF), that is 47% similar to human macrophage migration inhibitory factor (HuMIF), a proinflammatory cytokine. Because HuMIF is reported to be elevated in prostate cancer and inflammation plays an important role in the initiation and progression of cancers, we have explored a role for TvMIF in prostate cancer. Here, we show that TvMIF has tautomerase activity, inhibits macrophage migration, and is proinflammatory. We also demonstrate that TvMIF binds the human CD74 MIF receptor with high affinity, comparable to that of HuMIF, which triggers activation of ERK, Akt, and Bcl-2-associated death promoter phosphorylation at a physiologically relevant concentration (1 ng/mL, 80 pM). TvMIF increases the in vitro growth and invasion through Matrigel of benign and prostate cancer cells. Sera from patients infected with T. vaginalis are reactive to TvMIF, especially in males. The presence of anti-TvMIF antibodies indicates that TvMIF is released by the parasite and elicits host immune responses during infection. Together, these data indicate that chronic T. vaginalis infections may result in TvMIF-driven inflammation and cell proliferation, thus triggering pathways that contribute to the promotion and progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24843155      PMCID: PMC4050605          DOI: 10.1073/pnas.1321884111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  66 in total

1.  Protection from septic shock by neutralization of macrophage migration inhibitory factor.

Authors:  T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer.

Authors:  D-S Yu; J C Lin; D S Hsieh; S Y Chang; C F Lee
Journal:  Arch Androl       Date:  2006 Jul-Aug

3.  Trichomonas vaginalis in the prostate gland.

Authors:  W A Gardner; D E Culberson; B D Bennett
Journal:  Arch Pathol Lab Med       Date:  1986-05       Impact factor: 5.534

4.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction.

Authors:  J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1966-07       Impact factor: 11.205

5.  Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells.

Authors:  Katherine L Meyer-Siegler; Kenneth A Iczkowski; Lin Leng; Richard Bucala; Pedro L Vera
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

Review 6.  Interleukin-8, a chemotactic and inflammatory cytokine.

Authors:  M Baggiolini; I Clark-Lewis
Journal:  FEBS Lett       Date:  1992-07-27       Impact factor: 4.124

7.  Presence of a member of the mitochondrial carrier family in hydrogenosomes: conservation of membrane-targeting pathways between hydrogenosomes and mitochondria.

Authors:  S D Dyall; C M Koehler; M G Delgadillo-Correa; P J Bradley; E Plümper; D Leuenberger; C W Turck; P J Johnson
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

8.  Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer.

Authors:  Siobhan Sutcliffe; Edward Giovannucci; John F Alderete; Te-Hung Chang; Charlotte A Gaydos; Jonathan M Zenilman; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-05       Impact factor: 4.254

9.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.

Authors:  Diana Starlets; Yael Gore; Inbal Binsky; Michal Haran; Nurit Harpaz; Lev Shvidel; Shirly Becker-Herman; Alain Berrebi; Idit Shachar
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

Review 10.  Sex differences in the transmission, prevention, and disease manifestations of sexually transmitted diseases.

Authors:  Vandana K Madkan; Angela A Giancola; Karan K Sra; Stephen K Tyring
Journal:  Arch Dermatol       Date:  2006-03
View more
  55 in total

1.  Vasectomy: potential links to an increased risk of aggressive prostate cancer?

Authors:  Alexis R Gaines; Adriana C Vidal; Stephen J Freedland
Journal:  Expert Rev Anticancer Ther       Date:  2015-09-07       Impact factor: 4.512

2.  Prevalence of double-stranded RNA virus in Trichomonas vaginalis isolated in Italy and association with the symbiont Mycoplasma hominis.

Authors:  Valentina Margarita; Alessandra Marongiu; Nicia Diaz; Daniele Dessì; Pier Luigi Fiori; Paola Rappelli
Journal:  Parasitol Res       Date:  2019-11-07       Impact factor: 2.289

3.  Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial.

Authors:  Miguelle Marous; Wen-Yi Huang; Charles S Rabkin; Richard B Hayes; John F Alderete; Bernard Rosner; Robert L Grubb; Anke C Winter; Siobhan Sutcliffe
Journal:  Cancer Causes Control       Date:  2017-07-01       Impact factor: 2.506

4.  Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women.

Authors:  C A Gaydos; J Schwebke; J Dombrowski; J Marrazzo; J Coleman; B Silver; M Barnes; L Crane; P Fine
Journal:  Expert Rev Mol Diagn       Date:  2017-01-29       Impact factor: 5.225

5.  Trichomoniasis in older individuals: a preliminary report from Iran.

Authors:  Zohreh Momeni; Javid Sadraei; Bahram Kazemi; Abdolhossein Dalimi
Journal:  J Parasit Dis       Date:  2016-01-12

6.  Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.

Authors:  Fernanda Gobbi Bitencourt; Patrícia de Brum Vieira; Lucia Collares Meirelles; Graziela Vargas Rigo; Elenilson Figueiredo da Silva; Simone Cristina Baggio Gnoatto; Tiana Tasca
Journal:  Parasitol Res       Date:  2018-03-23       Impact factor: 2.289

7.  Trichomonas vaginalis infection in symbiosis with Trichomonasvirus and Mycoplasma.

Authors:  Raina Fichorova; Jorge Fraga; Paola Rappelli; Pier Luigi Fiori
Journal:  Res Microbiol       Date:  2017-03-31       Impact factor: 3.992

8.  Integrated morphologic and molecular analysis of Trichomonas vaginalis, Mycoplasma hominis, and human papillomavirus using cytologic smear preparations.

Authors:  I Nikas; A Hapfelmeier; M Mollenhauer; D Angermeier; M Bettstetter; R Götz; M Schmidmayr; V Seifert-Klauss; A Muckenhuber; U Schenck; Gregor Weirich
Journal:  Parasitol Res       Date:  2018-03-17       Impact factor: 2.289

9.  Persistence of Trichomonas vaginalis serostatus in men over time.

Authors:  Siobhan Sutcliffe; John F Alderete; Calvin Neace; Patrick A Joyce; Charlotte A Gaydos; James I A Huth; Lorelei A Mucci; Lisa B Signorello
Journal:  Cancer Causes Control       Date:  2015-07-30       Impact factor: 2.506

10.  Trichomonas vaginalis: a possible foe to prostate cancer.

Authors:  Ziwen Zhu; Kristoffer T Davidson; Andrew Brittingham; Mark R Wakefield; Qian Bai; Huaping Xiao; Yujiang Fang
Journal:  Med Oncol       Date:  2016-09-08       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.